Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 2006-30 | Other Identifier | CCRRC | |
| JT 1208 | Other Identifier | JeffTrial Number |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Pfizer | INDUSTRY |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This study is using the combination of radiation and antiangiogenic agents (agents that destroy existing blood vessels) seems to be an approach to tumor cure.
The combination of ionizing radiation and antiangiogenic agents seems to be a counterintuitive approach to tumor cure because oxygen is a potent radiosensitizer and a reduction in oxygen concentration would be expected following a reduction in tumor vasculature after antiangiogenic treatment.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Sunitinib plus Radiation | Experimental | Sunitinib plus Radiation |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Sunitinib | Drug | The use of the FDA approved drug sunitinib, used in an "off-label" manner with external beam radiation therapy. |
|
| Measure | Description | Time Frame |
|---|---|---|
| To evaluate the safety and toxicity profile of sunitinib when used with concurrent radiation therapy | The purpose of this study is to determine the safety of the combination of the antiangiogenic, sunitinib, when combined with external beam radiotherapy. | 2 years |
| Measure | Description | Time Frame |
|---|---|---|
| To measure urine VEGF | Urine VEGF may be a biomarker of response. This translational approach may be useful to determine who benefits from treatment. | 2 years |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Adam P Dicker, MD, PhD | Thomas Jefferson University | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Thomas Jefferson University | Philadelphia | Pennsylvania | 19107 | United States |
Not provided
| Label | URL |
|---|---|
| Kimmel Cancer Center at Thomas Jefferson University, an NCI-Designated Cancer Center | View source |
| Thomas Jefferson University Hospitals | View source |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| External Beam Radiation Therapy | Radiation | Radiotherapy will be administered Monday through Friday for a maximum of 8 weeks. Total dose will depend on the patient's disease site. |
|
|
| ID | Term |
|---|---|
| D009369 | Neoplasms |
| D006258 | Head and Neck Neoplasms |
| D010386 | Pelvic Neoplasms |
| D009423 | Nervous System Neoplasms |
| D013899 | Thoracic Neoplasms |
| ID | Term |
|---|---|
| D009371 | Neoplasms by Site |
| D009422 | Nervous System Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D000077210 | Sunitinib |
| ID | Term |
|---|---|
| D011758 | Pyrroles |
| D001393 | Azoles |
| D006573 | Heterocyclic Compounds, 1-Ring |
| D006571 | Heterocyclic Compounds |
| D007211 | Indoles |
| D006574 | Heterocyclic Compounds, 2-Ring |
| D000072471 | Heterocyclic Compounds, Fused-Ring |
Not provided
Not provided